|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALKBH6 |
Gene summary for ALKBH6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALKBH6 | Gene ID | 84964 |
| Gene name | alkB homolog 6 | |
| Gene Alias | ABH6 | |
| Cytomap | 19q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B4E3P3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84964 | ALKBH6 | LZE20T | Human | Esophagus | ESCC | 3.16e-03 | 1.22e-01 | 0.0662 |
| 84964 | ALKBH6 | LZE24T | Human | Esophagus | ESCC | 8.01e-19 | 4.00e-01 | 0.0596 |
| 84964 | ALKBH6 | P1T-E | Human | Esophagus | ESCC | 1.09e-04 | 2.50e-01 | 0.0875 |
| 84964 | ALKBH6 | P2T-E | Human | Esophagus | ESCC | 9.35e-10 | 1.88e-01 | 0.1177 |
| 84964 | ALKBH6 | P4T-E | Human | Esophagus | ESCC | 8.33e-13 | 2.64e-01 | 0.1323 |
| 84964 | ALKBH6 | P5T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.10e-01 | 0.1327 |
| 84964 | ALKBH6 | P8T-E | Human | Esophagus | ESCC | 6.36e-33 | 5.23e-01 | 0.0889 |
| 84964 | ALKBH6 | P9T-E | Human | Esophagus | ESCC | 1.57e-24 | 4.48e-01 | 0.1131 |
| 84964 | ALKBH6 | P10T-E | Human | Esophagus | ESCC | 3.75e-29 | 6.02e-01 | 0.116 |
| 84964 | ALKBH6 | P11T-E | Human | Esophagus | ESCC | 7.73e-16 | 4.81e-01 | 0.1426 |
| 84964 | ALKBH6 | P12T-E | Human | Esophagus | ESCC | 9.02e-11 | 2.38e-01 | 0.1122 |
| 84964 | ALKBH6 | P15T-E | Human | Esophagus | ESCC | 6.21e-15 | 2.75e-01 | 0.1149 |
| 84964 | ALKBH6 | P16T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.41e-01 | 0.1153 |
| 84964 | ALKBH6 | P17T-E | Human | Esophagus | ESCC | 2.60e-06 | 2.75e-01 | 0.1278 |
| 84964 | ALKBH6 | P19T-E | Human | Esophagus | ESCC | 2.95e-08 | 5.09e-01 | 0.1662 |
| 84964 | ALKBH6 | P20T-E | Human | Esophagus | ESCC | 6.15e-13 | 2.59e-01 | 0.1124 |
| 84964 | ALKBH6 | P21T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.93e-01 | 0.1617 |
| 84964 | ALKBH6 | P22T-E | Human | Esophagus | ESCC | 3.52e-19 | 3.23e-01 | 0.1236 |
| 84964 | ALKBH6 | P23T-E | Human | Esophagus | ESCC | 2.24e-15 | 3.53e-01 | 0.108 |
| 84964 | ALKBH6 | P24T-E | Human | Esophagus | ESCC | 3.89e-12 | 2.79e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALKBH6 | SNV | Missense_Mutation | rs756492251 | c.334N>A | p.Asp112Asn | p.D112N | Q3KRA9 | protein_coding | tolerated(0.09) | possibly_damaging(0.669) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ALKBH6 | SNV | Missense_Mutation | c.73G>A | p.Glu25Lys | p.E25K | Q3KRA9 | protein_coding | deleterious_low_confidence(0.02) | benign(0.025) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ALKBH6 | insertion | In_Frame_Ins | novel | c.421-1_421insGGTACA | p.Met140_Pro141insGlyThr | p.M140_P141insGT | Q3KRA9 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| ALKBH6 | SNV | Missense_Mutation | rs377096899 | c.331N>A | p.Val111Met | p.V111M | Q3KRA9 | protein_coding | tolerated(0.28) | benign(0.154) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ALKBH6 | SNV | Missense_Mutation | c.247N>A | p.Gly83Arg | p.G83R | Q3KRA9 | protein_coding | tolerated(0.05) | probably_damaging(0.962) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ALKBH6 | SNV | Missense_Mutation | novel | c.287N>A | p.Arg96Gln | p.R96Q | Q3KRA9 | protein_coding | deleterious(0.04) | benign(0.225) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ALKBH6 | SNV | Missense_Mutation | c.469N>A | p.Leu157Met | p.L157M | Q3KRA9 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ALKBH6 | SNV | Missense_Mutation | novel | c.287G>A | p.Arg96Gln | p.R96Q | Q3KRA9 | protein_coding | deleterious(0.04) | benign(0.225) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ALKBH6 | SNV | Missense_Mutation | novel | c.397N>C | p.Tyr133His | p.Y133H | Q3KRA9 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ALKBH6 | SNV | Missense_Mutation | c.155N>G | p.Tyr52Cys | p.Y52C | Q3KRA9 | protein_coding | tolerated(0.06) | probably_damaging(0.991) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |